Novartis Sues Par Over Dementia Patch Generic
According to the Swiss pharmaceutical giant, Woodcliff Lake, N.J.-based Par’s planned 13.3-milligram generic rivastigmine transdermal patches infringes upon U.S. Patent Number 6,335,031, a patent jointly owned by Novartis and German transdermal patch specialist LTS Lohmann Therapie-Systeme AG.
“There is a substantial and immediate controversy between plaintiffs and Par concerning the '031 patent,” the complaint said....
Already a subscriber? Click here to login